表阿霉素为主药物治疗94例恶性肿瘤的疗效和毒性观察

The Efficacy and Toxicity of Epirubicin Chemotherapy Regimens in 94 Cancer Patients

本组恶性肿瘤９４例，以恶性淋巴瘤、乳腺癌、胃癌、肺癌为主，病期以Ⅲ、Ⅳ期居多（８８．３％）。中位年龄５６岁，最大年龄７７岁，Ｋａｒｎｏｆｓｋｙ评分６０～９０分。根据病种，患者接受以表阿霉素为主的化学药物联合方案，如Ｅ—ＡＤＭ、ＣＥＯＰ、ＣＥＰ、ＦＥＣ、ＦＥＭ等，治疗２个疗程或２个疗程以上者参予疗效和毒性评价。结果：全组完全缓解率１９．１％（１８／９４），总有效率５８．５％（５５／９４），与同期我科采用阿霉素治疗恶性肿瘤的疗效相仿。毒性观察显示，表阿霉素为主方案的骨髓和消化道毒性低，心脏损害轻，适于伴心功不全或心电图异常患者使用。

Ninety four cases of proven malignancies including non-Hodgkin' s lymphomas, breast cancers, gastric cancers and lung cancers were treated with epirubicin chemotherapy reginens, such as CEOP (CTX + EPI + VCR + PDN ), CEP (CTX + EPI + PDD), FEC (5 - Fu +EPI+CTX),FEM (5-Fu +EPI+MMC). Of them, 83 cases (88. 3%) were of stage Ⅲ or Ⅳ, with a median age of 56 years (ranging from 21 ～ 77). After 2 or more courses of chemotherapy, the efficacy and toxicity were evaluated. The total objective response rate and complete response rate were 58. 5% and 19. 1 %, respectively. Mild to moderate GI and bone marrow toxicities were main side effects. No evident cardiotoxicity was found in majority of the patients. The results show that epirubicin chemotherapy regimens were effective and were suitable to the patients with heart failure or abnormal electrocardiogram(ECG).